Trastuzumab Deruxtecan for HER2-Overexpressing Metastatic NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Lancet Oncol 2024 Apr 01;25(4)439-454, EF Smit, E Felip, D Uprety, M Nagasaka, K Nakagawa, L Paz-Ares Rodríguez, JM Pacheco, BT Li, D Planchard, C Baik, Y Goto, H Murakami, A Saltos, K Pereira, A Taguchi, Y Cheng, Q Yan, W Feng, Z Tsuchihashi, PA JänneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.